Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H44N2 |
Molecular Weight | 336.5982 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1
InChI
InChIKey=SERHTTSLBVGRBY-UHFFFAOYSA-N
InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15970928
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15970928
Atiprimod is an oral azaspirane which was initially developed by Smith Kline and French Laboratories for treating rheumatoid arthritis (discontinued in phase I). Due to its anti-inflammatory, antineoplastic, and antiangiogenic properties, the drug was tested in patients with Neuroendocrine Carcinoma and Multiple Myeloma and reached phase II (discontinued). In vitro studies revealed that atiprimod exerts its action by inhibiting the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. | 2005 Jun 1 |
|
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. | 2007 Dec |
Sample Use Guides
Neuroendocrine Carcinoma: Atiprimod is administered orally as a single daily dose of 120 mg/day for 14 days, followed by a 14-day treatment-free period. Multiple Myeloma: atiprimod was given at ten dose levels - 30, 60, 90, 120, 180, 240, 300, 360, 420, and 480 mg/day or 180, 240, 300, 360, 420, and 480 mg/day (in combination with ursodiol).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15970928
U266-B1 cells were incubated with 8 uM atiprimod to measure how the drug suppresses IL-6 production. Atiprimod attenuated IL6 supernatant levels to 23, 42, 53, and 130 pg/ml at 1, 6, 8, and 16 hours, respectively. NF-kB activity in the same cell line was blocked after 4 h of incubation with 50 uM atiprimod and after 24 h when using 8 uM of the drug. The percentage of cells undergoing apoptotic cell death also increased from 10.89 to 46.27% after exposure to 8 uM atiprimod.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C274
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
||
|
FDA ORPHAN DRUG |
167103
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
129869
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
100000086653
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
DB05513
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
ATIPRIMOD
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
SUB05595MIG
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
C099015
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL103735
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
MG7D3QD743
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
7506
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
C52184
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
DTXSID10153834
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY | |||
|
123018-47-3
Created by
admin on Fri Dec 15 16:15:30 GMT 2023 , Edited by admin on Fri Dec 15 16:15:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)